Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting

References

• MocroftALedergerberBKatlamaCEuroSIDA study groupDecline in the AIDS and death rates in the EuroSIDA study: an observational studyLancet20033629377222912853195
   PubMed Web of Science ®Google Scholar
• Antiretroviral Therapy Cohort CollaborationLife expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesLancet7262008372963529329918657708
   PubMed Web of Science ®Google Scholar
• VolberdingPADeeksSGAntiretroviral therapy and management of HIV infectionLancet20103769734496220609987
   PubMed Web of Science ®Google Scholar
• FreedbergKALosinaEWeinsteinMCThe cost effectiveness of combination antiretroviral therapy for HIV diseaseN Engl J Med20013441182483111248160
   PubMed Web of Science ®Google Scholar
• National Committee on AIDS, Ministry of Health National Commission for the Fight Against AIDSLinee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1 [Italian guidelines on antiretroviral drugs and the diagnostic-clinical management of HIV patients]2012 Italian. Available at: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1793_allegato.pdfAccessed September 15, 2013
   Google Scholar
• NachegaJBRosenkranzBPhamPATwice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?Patient Prefer Adherence2011564565122259241
   PubMed Web of Science ®Google Scholar
• MaggioloFRipamontiDAriciCSimpler regimens may enhance adherence to antiretrovirals in HIV-infected patientsHIV Clin Trials20023537137812407486
   PubMedGoogle Scholar
• StoneVEJordanJTolsonJMillerRPilonTPerspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherenceJ Acquir Immune Defic Syndr200436380881615213564
   PubMed Web of Science ®Google Scholar
• BoyleBAJayaweeraDWittMDGrimmKMaaJFSeekinsDWRandomization to once-daily stavudine extended release/lamivudine/efavirenz |versus a more frequent regimen improves adherence while maintaining viral suppressionHIV Clin Trials20089316417618547903
   PubMed Web of Science ®Google Scholar
• AiroldiMZaccarelliMBisiLOne-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjectsPatient Prefer Adherence2010411512520517472
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA)Atripla [summary of European public assessment report]LondonEMA2009 [updated October 3, 2012]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000797/human_med_000657.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125Accessed June 10, 2013
   Google Scholar
• Lombardy RegionSocial and Health Care Plan. No. 937/2010MilanLombardy Region2010 Italian. Available at: http://www.sanita.regione.lombardia.it/shared/ccurl/956/366/DGRregole_e_allegati.zipAccessed June 10, 2012
   Google Scholar
• Lombardy RegionApprovazione del documento avente peroggetto Percorso Diagnostico Terapeutico (PDT) per il paziente affetto da malattia HIV/AIDS [Therapeutic and diagnostic path (PDT) for the patient with HIV/AIDS disease] Decree no 7485852011MilanLombardy Region2012 Italian. Available at: http://www.sanita.regione.lombardia.it/cs/Satellite?c=Page&childpagename=DG_Sanita/Page/NormativaDetail&pagename=DG_SANWrapper&cid=1213275902673&keyid=3520Accessed June 10, 2012
   Google Scholar
• Agenzia Italiana del Faramco [AIFA; Italian Drug Agency]Negoziazione e rimborsabilitá [Negotiation and reimbursement; web page on the Internet]RomeAIFA2013 Italian. Available at: http://www.agenziafarmaco.gov.it/it/content/negoziazione-e-rimborsabilit%C3%A0Accessed November 13, 2011
   Google Scholar
• IstatIndice dei prezzi al consumo per le rivalutazioni monetarie [Consumer Price Index for inflation adjustments]RomaIstituto nazionale di statistica Available from: http://www.istat.it/it/archivio/30440Accessed November 7, 2013
   Google Scholar
• LiottaGCaleoGMMancinelliSAnalysis of survival in HIV-infected subjects according to socio-economic resources in the HAART eraAnn Ig20082029510418590041
   PubMedGoogle Scholar
• MoeremansKAnnemansLLöthgrenMCost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UKPharmacoeconomics201028Suppl 110712821182347
   PubMed Web of Science ®Google Scholar
• ColomboGLColangeliVDi BiagioADi MatteoSViscoliCVialePCost-effectiveness analysis of initial HIV treatment under Italian guidelinesClinicoecon Outcomes Res2011319720522163167
   PubMedGoogle Scholar
• RizzardiniGBonfantiPCarenziLCost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern ItalyTher Clin Risk Manag2012837738423028230
   PubMed Web of Science ®Google Scholar
• FogliaEBonfantiPRizzardiniGCost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real worldPLoS One201382e5777723460905
   PubMed Web of Science ®Google Scholar
• RizzardiniGRestelliUBonfantiPThe cost of HIV disease in Northern Italy: the payer’s perspectiveJ Acquir Immune Defic Syndr201157321121721546850
   PubMed Web of Science ®Google Scholar
• RizzardiniGRestelliUBonfantiPCost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhile?Clinicoecon Outcomes Res2012424525222973114
   PubMedGoogle Scholar
• SimpsonKNLuoMPChumneyESunEBrunSAshrafTCost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infectionHIV Clin Trials20045529430415562370
   PubMed Web of Science ®Google Scholar
• ColomboGLDi MatteoSMaggioloFAntiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimenClinicoecon Outcomes Res20135596823430273
   PubMedGoogle Scholar
• AntinoriAMarcotullioSAmmassariAItalian HIV Guidelines Working GroupItalian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011New Microbiol201235211315922707127
   PubMed Web of Science ®Google Scholar
• d’Arminio MonforteALepriACRezzaGInsights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-PatientsAIDS200014549950710780712
   PubMed Web of Science ®Google Scholar
• PatersonDLSwindellsSMohrJAdherence to protease inhibitor therapy and outcomes in patients with HIV infectionAnn Intern Med20001331213010877736
   PubMed Web of Science ®Google Scholar
• BangsbergDRPerrySCharleboisEDNon-adherence to highly active antiretroviral therapy predicts progression to AIDSAIDS20011591181118311416722
   PubMed Web of Science ®Google Scholar
• LimaVDHarriganRBangsbergDRThe combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over timeJ Acquir Immune Defic Syndr200950552953619223785
   PubMed Web of Science ®Google Scholar
• AntinoriACozzi-LepriAAmmassariAAdICoNA Study GroupRelative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAARTAntivir Ther20049229129615134192
   PubMed Web of Science ®Google Scholar
• BorghiCCiceroAFGAderenza e persistenza in terapia. [Adherence and persistence in therapy]Giornale Italiano di Farmacoeconomia e Farmaco Utilizzazione200812513 Italian
   Google Scholar